
Report ID: SQMIG35A2591
Skyquest Technology's expert advisors continuously track and analyze the latest developments and updates related to microneedle drug delivery systems market. Our team of analysts stay abreast of all the recent news stories shaping the industry including new product launches by major companies, strategic partnerships, M&As, Patent filings and industry and regulatory developments.
In December 2023, Kindeva Drug Delivery and Orbia Advance Corporation's Fluorinated Solutions business announced a collaboration. They plan to change over existing pressurized Metered Dose Inhaler (pMDI) items to Koura's supportable clinical fuel, HFA 152a (Zephex 152a). This association centers around decreasing carbon emissions byproducts from respiratory healthcare by progressing to low global warming alteration expected pMDIs. The objective is to work with the change of pMDI items to harmless to the ecosystem force 152a and move them through the clinical turn of events, at last giving patients more practical inhaler choices.
In October 2023, JW Pharmaceutical, a Korean pharmaceutical organization, declared an examination organization with Theraject Asia, a microneedle Research and Development Organization, to foster a hair loss treatment. JW Pharmaceutical's Drug Research Center will utilize Theraject Asia's high-level stage to make microneedle answers for treating people going bald.
REQUEST FOR SAMPLE
Microneedle Drug Delivery Systems Market size was valued at USD 3.02 Billion in 2023 and is poised to grow from USD 3.23 Billion in 2024 to USD 5.48 Billion by 2032, growing at a CAGR of 6.83% during the forecast period (2025-2032).
Currently, the global microneedle drug delivery systems market is characterized by intense competition and dynamic advancements. Several prominent players are dominating the landscape, while numerous emerging companies are making strides to gain market share. Established pharmaceutical and medical device companies are actively investing in research and development to develop innovative microneedle-based products. These companies are leveraging their extensive resources, regulatory expertise, and established distribution networks to position themselves favorably in the market. '3M (USA)', 'Becton, Dickinson and Company (BD) (USA)', 'Johnson & Johnson (USA)', 'Corium, Inc. (USA)', 'Zosano Pharma Corporation (USA)', 'Medtronic plc (Ireland)', 'TheraJect, Inc. (USA)', 'Vetter Pharma International GmbH (Germany)', 'Lohmann Therapie-Systeme AG (Germany)', 'NanoPass Technologies Ltd. (Israel)'
The aging global population is driving the demand for more convenient and user-friendly drug delivery methods, fostering the adoption of microneedle systems.
Growing Demand for Pain-Free Drug Delivery: Microneedle drug delivery systems offer a less painful and minimally invasive alternative to traditional injections, driving their adoption among patients and healthcare providers.
The Asia Pacific region is projected to experience substantial growth in the microneedle drug delivery systems market, attributed to factors such as a growing population, changing lifestyles, increased patient awareness, and rising per capita expenditure. Moreover, the region's economic growth and efforts to improve healthcare infrastructure, particularly in countries like India and China, are further supporting this growth. Additionally, the efficacy of cosmetic products is improving, which contributes to the advancement of healthcare facilities.
Want to customize this report? This report can be personalized according to your needs. Our analysts and industry experts will work directly with you to understand your requirements and provide you with customized data in a short amount of time. We offer $1000 worth of FREE customization at the time of purchase.
Feedback From Our Clients
Report ID: SQMIG35A2591
sales@skyquestt.com
USA +1 351-333-4748